DengiAll

DengiAll :Recently, India crossed the 50% enrolment mark in Phase III clinical trials of its indigenous dengue vaccine, ‘DengiAll’, with over 7,000 volunteers participating across 20 trial sites nationwide.

• About DengiAll : Developed by Panacea Biotec, an Indian pharmaceutical company, under a licensing agreement with the U.S. National Institutes of Health (NIH).

o Vaccine Type: It is a single-dose tetravalent live attenuated vaccine, meaning it targets all four strains of the dengue virus and aims to induce a balanced immune response.

o Origin : The TV003/TV005 vaccine strain was originally developed by the NIH, USA.

• Dengue: Viral infection transmitted through the bite of infected Aedes species mosquitoes.

o Found: Tropical & sub-tropical climates worldwide, mostly in urban and semi-urban areas.

o Symptoms: Usually begin 4–10 days after infection and last for 2–7 days. Symptoms may include: high fever, severe headache, pain behind the eyes, nausea, vomiting, swollen glands and rash. Severe Symptoms: severe abdominal pain, persistent vomiting, rapid breathing, bleeding gums or nose, fatigue and restlessness.

o Treatment: There is no specific treatment for dengue.